Geoffrey R. Oxnard
杰弗里·奥克斯纳德
MD
Vice President, Oncology Research & Development, AstraZeneca; Affiliate Faculty, Dana-Farber Cancer Institute阿斯利康肿瘤研究与开发副总裁；达纳-法伯癌症研究所附属教员
👥Biography 个人简介
Geoffrey R. Oxnard, MD is Vice President of Oncology Research & Development at AstraZeneca and Affiliate Faculty at Dana-Farber Cancer Institute, where he previously held a faculty position in thoracic oncology. He is internationally recognized as one of the pioneers of liquid biopsy and cell-free DNA (cfDNA) technology in lung cancer, having conducted foundational studies demonstrating that plasma genotyping can noninvasively detect EGFR sensitizing mutations, T790M resistance mutations, and acquired resistance mechanisms with clinically actionable sensitivity and turnaround time. At Dana-Farber, Dr. Oxnard led a research program that established plasma genotyping as a routine clinical practice for EGFR mutation testing and resistance monitoring, publishing multiple validation studies now cited as the evidence base for FDA-approved plasma EGFR companion diagnostics. In his current industry role, he has led biomarker strategy for major AstraZeneca lung cancer programs, including FLAURA2—the phase III trial adding platinum-pemetrexed chemotherapy to first-line osimertinib in EGFR-mutant advanced NSCLC, which demonstrated significantly improved PFS in the combination arm and has prompted re-evaluation of standard first-line approaches in high-risk patients. Dr. Oxnard has also contributed to minimal residual disease (MRD) ctDNA assay development for early-stage NSCLC surveillance.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Plasma cfDNA Genotyping for EGFR Detection and Resistance Monitoring
Conducted landmark validation studies of plasma cell-free DNA genotyping for noninvasive EGFR mutation detection, demonstrating clinical sensitivity of 60–70% for sensitizing mutations and >70% for T790M in plasma, and establishing that plasma genotyping can accurately identify acquired resistance mechanisms including MET amplification and EGFR C797S.
FLAURA2 — Osimertinib plus Chemotherapy as First-Line Standard
Led biomarker strategy for and contributed to the FLAURA2 phase III trial demonstrating that adding platinum-pemetrexed chemotherapy to first-line osimertinib significantly improved progression-free survival (25.5 vs 16.7 months) in EGFR-mutant advanced NSCLC, particularly in patients with TP53 co-mutations and high tumor burden, reshaping first-line treatment considerations.
Liquid Biopsy Technology Development and Regulatory Science
Contributed to the analytical and clinical validation framework for plasma cfDNA companion diagnostics, co-authoring regulatory-science papers that informed FDA acceptance of liquid biopsy for EGFR mutation testing in NSCLC, and establishing criteria for sensitivity, specificity, and clinical reporting of cfDNA genotyping in oncology practice.
MRD and ctDNA Dynamics in Early-Stage NSCLC
Advanced the field of minimal residual disease (MRD) detection in resected early-stage NSCLC, demonstrating that ctDNA positivity after surgical resection predicts relapse with high specificity and that ctDNA dynamics during adjuvant therapy reflect treatment benefit — forming the basis for ctDNA-guided adjuvant clinical trials.
Representative Works 代表性著作
Osimertinib plus platinum-pemetrexed in newly diagnosed EGFR-mutated advanced NSCLC (FLAURA2)
New England Journal of Medicine (2023)
FLAURA2 phase III trial demonstrating that osimertinib plus chemotherapy significantly improved PFS (25.5 vs 16.7 months) over osimertinib alone in EGFR-mutant advanced NSCLC, with particular benefit in TP53 co-mutated and high tumor burden subgroups.
Noninvasive assessment of acquired resistance to EGFR-targeted therapies in non-small-cell lung cancer by next-generation sequencing of plasma cell-free DNA
Annals of Oncology (2014)
Validation study demonstrating that plasma cell-free DNA genotyping can detect EGFR T790M and other acquired resistance mechanisms in NSCLC with clinically meaningful sensitivity, establishing liquid biopsy as a practical resistance monitoring tool.
Plasma genotyping for lung cancer: ASCO point/counterpoint
Journal of Clinical Oncology (2016)
Influential commentary establishing clinical evidence thresholds and practical guidance for integrating plasma cfDNA genotyping into lung cancer clinical practice.
Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib
JAMA Oncology (2018)
Comprehensive plasma and tissue characterization of acquired resistance mechanisms to osimertinib, identifying MET amplification, C797S, RAS/MAPK, and cell cycle alterations with implications for combinatorial resistance-targeting strategies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 杰弗里·奥克斯纳德 的研究动态
Follow Geoffrey R. Oxnard's research updates
留下邮箱，当我们发布与 Geoffrey R. Oxnard（AstraZeneca / Foundation Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment